US 10745481
Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
granted A61KA61K2039/505A61K31/537
Quick answer
US patent 10745481 (Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof) held by CytomX Therapeutics, Inc. expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CytomX Therapeutics, Inc.
- Grant date
- Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 88
- CPC classes
- A61K, A61K2039/505, A61K31/537, A61K47/68033, A61K47/6849